CT-1812 is under clinical development by Cognition Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect CT-1812’s likelihood of approval (LoA) and phase transition for Alzheimer’s Disease took place on 02 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CT-1812 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
CT-1812 (CT-018120, Elayta) is under development for the treatment of mild to moderate Alzheimer's disease, Parkinson’s disease, lewy body dementia and dry age related macular degeneration. It is administered orally in form of capsule. It is a small molecule which acts by targeting sigma-2/PGRMC1 and Abeta (Amyloid Beta Peptide) oligomers.
Cognition Therapeutics overview
Cognition Therapeutics (CogRx) is a drug discovery and development company. It discovers and develops small molecule therapeutics for Alzheimer’s disease and other neurocognitive disorders. The company uses its proprietary biology and chemistry platforms for the development of novel drug targets and disease-modifying therapies for the treatment of central nervous system disorders. It conducts clinical trials on its drug candidate CT1812 for the treatment of Alzheimer’s disease. The company uses screening strategies to identify small molecules capable of blocking the central toxicity of soluble oligomeric proteins. CogRx is headquartered in Purchase, New York, the US.
Quick View CT-1812 LOA Data
|Highest Development Stage|